

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7698863

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ATHYRIUM OPPORTUNITIES III ACQUISITION LP	12/16/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SOCIETAL CDMO, INC.
<b>Street Address:</b>	1 E. UWCHLAN AVENUE
<b>City:</b>	EXTON
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19341
<b>PROPERTY NUMBERS Total: 10</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	9795559
Patent Number:	8470862
Patent Number:	9078883
Patent Number:	9446025
Patent Number:	7759496
Application Number:	15702319
Application Number:	11951114
Application Number:	13257214
Application Number:	13391154
Application Number:	14411060
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(404)885-3900
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	4048853145
<b>Email:</b>	eric.thanski@troutman.com
<b>Correspondent Name:</b>	TROUTMAN PEPPER HAMILTON SANDERS LLP
<b>Address Line 1:</b>	600 PEACHTREE STREET, NE
<b>Address Line 2:</b>	SUITE 3000
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30308
<b>NAME OF SUBMITTER:</b>	JAMES E. SCHUTZ

PATENT

<b>SIGNATURE:</b>	/James E. Schutz/
<b>DATE SIGNED:</b>	12/16/2022
<b>Total Attachments: 3</b> source=Release of Security Interest in Patents - Societal CDMO Inc fka Recro Pharma Inc (Executed)#page1.tif source=Release of Security Interest in Patents - Societal CDMO Inc fka Recro Pharma Inc (Executed)#page2.tif source=Release of Security Interest in Patents - Societal CDMO Inc fka Recro Pharma Inc (Executed)#page3.tif	

## TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS dated as of December 16, 2022 (this “Release”), is made by Athyrium Opportunities III Acquisition LP, a Delaware limited partnership, as Administrative Agent (the “Administrative Agent”), in favor of Societal CDMO, Inc. f/k/a Recro Pharma, Inc., a Pennsylvania company (“Company”).

**WHEREAS**, pursuant to that certain Security Agreement dated as of November 17, 2017 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”), by and among the Company, the Administrative Agent for the Secured Parties referenced therein, and others party thereto, the Company granted to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in, and continuing lien upon, any and all right, title and interest of Company’s Patents and patent licenses, including those patents, patent licenses and patent applications set forth on Schedule 1 attached hereto (collectively, the “Patent Collateral”); and

**WHEREAS**, pursuant to the Security Agreement, the Company executed and delivered to Administrative Agent the Notice of Grant of Security Interest in Patents dated as of November 17, 2017, which was recorded at the United States Patent and Trademark Office (“USPTO”) on November 17, 2017, at Reel 044166 Frame 0008, and correctively re-recorded at the USPTO on March 8, 2019, at Reel 048540 Frame 0415 (“Notice”).

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent and Company agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or Notice.

**SECTION 2. Termination and Release.** Administrative Agent, on behalf of the Secured Parties, without any representation, warranty, recourse, or undertaking of any kind (whether express or implied), hereby:

(a) terminates, cancels, discharges, and releases the continuing security interest in, and continuing lien upon, any and all right, title and interest of Company’s Patent Collateral, including those patents, patent licenses and patent applications set forth on Schedule 1 attached hereto, granted pursuant to the Security Agreement or Notice; and

(b) authorizes the recordation of this Release with the USPTO at Company’s expense.

**SECTION 3. Choice of Law.** This Release and obligations of the parties hereunder, and all of their successors, assigns, and transferees, shall be governed by and construed in accordance with the laws of the State of New York.


**IN WITNESS WHEREOF**, the Administrative Agent, on behalf of the Secured Parties, has caused this Release to be duly executed as of the date first set forth above.

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES III ACQUISITION LP,  
a Delaware limited partnership, as Administrative Agent

By: ATHYRIUM OPPORTUNITIES  
ASSOCIATES III LP, its General Partner

By: ATHYRIUM OPPORTUNITIES  
ASSOCIATES III GP LLC, the General Partner  
of Athyrium Opportunities Associates III LP

By:   
Name: Rashida Adams  
Title: Authorized Signatory

**Schedule 1**

**Societal CDMO, Inc. f/k/a Recro Pharma, Inc.  
(Pennsylvania corporation)**

**U.S. Patents**

**U.S. Patents Owned by Societal CDMO, Inc. f/k/a Recro Pharma, Inc.**

<b><u>Patent No.</u></b>	<b><u>Application No.</u></b>	<b><u>Filing Date</u></b>	<b><u>Owner</u></b>
9,795,559	13/711,407	12/11/12	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
	15/702,319	9/12/17	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
8,470,862	13/096,387	4/28/11	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
9,078,883	13/925,271	6/24/13	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
9,446,025	14/738,717	6/12/15	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
7,759,496	10/537,622	3/29/06	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.

**Patent Licenses - U.S. Patents Licensed to Societal CDMO, Inc. f/k/a Recro Pharma, Inc.**

Administrative Agent is releasing its security interest in Company's rights as licensee to the following patents:

<b><u>Patent No.</u></b>	<b><u>Application No.</u></b>	<b><u>Filing Date</u></b>	<b><u>Owner</u></b>	<b><u>Licensee</u></b>
8,148,398	11/951,114	12/5/07	Cornell Research Foundation, Inc.	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
8,592,451	13/257,214	12/12/11	Cornell University	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
9,220,700	13/391,154	5/7/12	Cornell University	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
9,156,826	14/411,060	12/23/14	Cornell University	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.